Diabetic peripheral neuropathy is a degeneration
|
|
- Mabel Hood
- 5 years ago
- Views:
Transcription
1 DIABEIC PERIPHERAL NEUROPAHY: LINKING MICROVASCULAR EIOLOGY O POENIAL REAMENS* Rayaz A. Malik, MB.ChB, PhD, MRCP ABSRAC For many years clinicians thought that damage to the microvasculature is the underlying cause of diabetic peripheral neuropathy, diabetic nephropathy, and diabetic retinopathy. Now studies have provided considerable epidemiologic, pathologic, pathophysiologic, and molecular evidence to support this long-held clinical hypothesis. Molecular studies have elucidated the sequence of events in microvascular damage and identified several key pathways (eg, protein kinase C [PKC], advanced glycation end products, polyol, and hexosamine) that lead to endothelial cell dysfunction and death and, ultimately, to tissue damage in the retinas, kidneys, and nerves. hese pathways, therefore, are potential therapeutic targets. Structural abnormalities in resistance vessels are preceded by functional abnormalities, which are driven by oxidative stress. Superoxide levels are increased and maximal vasodilation is decreased in the streptozotocin diabetic rat. In addition, there is a significant shift in vascular endothelial sensitivity in patients with type 2 diabetes mellitus, and the shift is even more pronounced in those patients with diabetes and hypertension. Impaired vasodilation and an abnormal myogenic response provide no protection to downstream vessels, thus setting the stage for basement membrane thickening and microvascular sclerosis. *Based on a presentation given by Dr Malik at a symposium held on the occasion of the 40th Annual Meeting of the European Association for the Study of Diabetes. Senior Lecturer and Consultant Physician, Academic Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom. Address correspondence to: Rayaz A. Malik, MB.ChB, PhD, Academic Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester, UK M13 9WL. rayaz.a.malik@man.ac.uk. here is evidence that basement membrane thickening, a hallmark of diabetic microangiopathy, is present in late-stage diabetic peripheral neuropathy. However, recent studies have shown that it is also present in patients with diabetic peripheral impaired glucose tolerance and early stage diabetic peripheral neuropathy. Angiotensin II receptor blockade for the treatment of vascular dysfunction partially restores the blunted vasodilatory response and normalizes the shift in blood vessel sensitivity in patients with type 2 diabetes mellitus. Similarly, angiotensinconverting enzyme inhibition results in significant and meaningful electrophysiologic improvements in nerve conduction velocity, M-wave amplitude, and F-wave latency in patients with mild diabetic peripheral neuropathy. Encouraging data from recently completed studies of the PKC-β inhibitor ruboxistaurin show that it improves symptom scores and nerve function scores in patients with diabetic peripheral neuropathy. (Adv Stud Med. 2005;5(3A):S144-S149) Diabetic peripheral neuropathy is a degeneration of the peripheral nerves that starts in the distal extremities and then moves proximally. Precisely what causes this type of nerve damage is not yet fully understood, but identifying the cause is the key to developing effective treatment. Clinicians have thought that damage to the microvasculature could be the underlying cause of not only diabetic retinopathy and diabetic nephropathy but also diabetic peripheral neuropathy. In 1974, Klaes Lundbaek, a practicing diabetologist, proposed the unitary hypothesis of diabetic microangiopathy after observing that patients with retinopathy also had some S144 Vol. 5 (3A) March 2005
2 degree of nephropathy and neuropathy. 1 Without the benefit of molecular studies, he hypothesized that microvascular disease was common to these 3 diabetic microvascular complications. As described later in this article, there is now considerable epidemiologic, pathologic, pathophysiologic, and molecular evidence to support this clinical hypothesis. EPIDEMIOLOGY AND RISK FACORS he Rochester Diabetic Neuropathy Study, a highly acclaimed prospective study of diabetic neuropathy, was conducted by neurologists who examined a broad range of risk factors in patients with different stages of diabetic neuropathy to determine which risk factors had the most impact on outcomes. 2 Assessed risk factors included fasting plasma glucose, glycosylated hemoglobin (HbA 1c ), and duration of diabetes mellitus all of which were considered extremely important in the development and progression of diabetic neuropathy. However, as the investigators surprisingly discovered, the risk factors that most strongly predicted the development and progression of neuropathy were the severity of retinopathy and 24-hour proteinuria. 2 his finding provides strong epidemiologic evidence to support the unitary hypothesis of diabetic microangiopathy. MOLECULAR BASIS OF MICROVASCULAR DAMAGE All of these pathways have a common source (ie, oxidative stress) and a common site where their deleterious effects are exerted (ie, the endothelium). 3-5 Research on the molecular basis of microvascular damage suggests the following sequence of events: excess glucose induces the formation of superoxides that produce mitochondrial oxidative stress. his stress drives several key pathways that are operative in the endothelium (the microvasculature) where they lead to endothelial cell dysfunction and death and, ultimately, to tissue damage in the retinas, kidneys, and nerves. 3-5 hese pathways include protein kinase C (PKC), advanced glycation end products (AGEs), NFκB, polyol flux, and hexosmine flux. Most of the research over the past 25 years has focused on the polyol and AGE pathways, but recent attention has shifted to the PKC pathway. All of these pathways have a common source (ie, oxidative stress) and a common site where their deleterious effects are exerted (ie, the endothelium). 3-5 herefore, blocking these pathways to deter damage to the endothelium is a viable approach to developing an effective therapy for diabetic microvascular complications. MICROVASCULAR DAMAGE O PERIPHERAL NERVES Damage to the endoneurial capillaries supplying the peripheral nerves leads to damage of the nerve fibers and eventually to signs and symptoms of painful diabetic neuropathy or loss of sensation and foot ulceration. Proximal epineurial vessels mediate much of the downstream damage to the endoneurial vessels. herefore, the crux of the problem is to determine what happens in the epineurial vessels (ie, the arterioles and venules) of the peripheral nerves to permit the progression to diabetic neuropathy. Because the retina is easily visualized, the vascular abnormalities, such as attenuation of the arterioles, arteriovenous shunting, and new vessel formation, seen in patients with diabetic retinopathy are considered the hallmarks of diabetic microangiopathy. Importantly, and in line with the unitary hypothesis of diabetic microangiopathy, these same epineurial abnormalities have been demonstrated in peripheral nerves. 6 PAHOPHYSIOLOGIC FACORS Structural abnormalities in resistance vessels, such as the epineurial arterioles, are preceded by functional abnormalities, which are driven by oxidative stress. Animal studies have shown that superoxide levels are increased and maximal vasodilation is decreased in the epineurial arterioles of diabetic animals, as compared with control models. 7,8 However, the same studies also showed that treatment with antioxidants, such as α-lipoic acid, partially restores vascular function in terms of the capacity for vasodilation and the sensitivity of the blood vessel. Similar research demonstrating functional vascular abnormalities involved human volunteers. However, because epineurial vessels are difficult to obtain from humans, resistance vessels that behave exactly as epineurial vessels have been used instead. In a study by Advanced Studies in Medicine S145
3 Schofield et al, vasodilation was clearly compromised in patients with type 2 diabetes mellitus compared to healthy control subjects because of an almost complete absence of the Bk Ca channel that is key to the mechanism leading to vasodilation. 9 Oxidative stress is the underlying cause of the loss of this channel in the epineurial vessels of patients with diabetes. When the investigators compared the vascular response to the agonist acetylcholine, they found a significant reduction in maximal vasodilatory capacity in patients with type 2 diabetes mellitus, as compared with that found in the healthy control subjects. 9 Researchers also found a significant shift in vascular endothelial sensitivity in the patients with diabetes. he shift was accentuated further by the presence of hypertension, suggesting that whereas diabetes alone limits the vessel s capacity to dilate (thus leading to ischemia), diabetes plus hypertension limits the capacity for vasodilation even further. he shift in sensitivity is, in fact, a double-edged sword. he blood vessels serve 2 purposes: provide blood flow to the tissues and, at the level of the resistance vessels, provide a means of protecting the distal capillaries from too much blood flow (a physiologic attribute of all resistance vessels known as the myogenic response). As shown in Figure 1, a slow increase in blood pressure flow (passive pressure) increases the luminal diameter of the blood vessel and causes it to dilate in healthy and diabetic individuals. 9 However, when blood pressure outflow is increased quickly (active pressure), the natural response of the resistance vessels is to contract, slow down blood flow downstream, and prevent damage to the distal capillaries. What actually occurs in healthy individuals is that the blood vessel closes down when the blood pressure level is increased quickly, and then the blood vessel re-opens when the blood pressure level is high. By comparison, the vessel continues to dilate in patients with diabetes, providing no protection downstream and setting the stage for basement membrane thickening and microvascular sclerosis. hese changes in vasodilation and myogenic response in diabetic patients, as compared with healthy control subjects, are shown schematically in Figure 2. PAHOLOGIC FACORS Basement membrane thickening is a hallmark of diabetic microangiopathy, occurring in the small vessels of the eyes, kidneys, and nerves in patients with diabetes. Although studies show that basement membrane thickening is present in late-stage neuropathy, many in the medical community want evidence that Figure 1. Myogenic Response of Resistance Vessels Lumen diameter, µm Diabetes Control * * Pressure, mm Hg * Passive pressure Active pressure *P <.05 Adapted with permission from Schofield et al. Circulation. 2002;106: Figure 2.Vascular Function in Patients with Diabetes Compared to Controls CONROL DIABEIC CONROL DIABEIC Impaired vasodilation Abnormal myogenic response S146 Vol. 5 (3A) March 2005
4 basement membrane thickening and other pathologic changes associated with diabetic neuropathy also occur at an early stage of the disease. An increasing body of medical literature demonstrates that such early changes are present. In 3 studies, approximately 33% of patients who presented to neurologists with painful symptoms suggestive of neuropathy had impaired glucose tolerance; biopsies of sural nerve tissue from these patients clearly showed damage to the small C fibers In another study involving 10 patients with impaired glucose tolerance, sural nerve biopsies revealed no loss of large myelinated nerve fibers, but they did show considerable damage to small nerve fibers. 13 Furthermore, the endoneurial capillary walls showed pericyte and basement membrane changes, with the changes more pronounced in the patients with symptoms of diabetic peripheral neuropathy than in patients without symptoms. A recently completed study involving 14 patients with type 1 and type 2 diabetes mellitus and minimal or subclinical diabetic peripheral neuropathy at baseline found that pathologic changes in small nerve fibers and endoneurial vessels were present at the early stage of the disease. 14 Patients in the study had normal vibration sensation, normal thermal discrimination, and near-normal nerve conduction velocity at baseline examination. Sural nerve biopsies were done at this time, and patients were observed for 10 years for progression of neuropathy. Over the course of the follow-up care, patients showed the typical signs of progression of diabetic peripheral neuropathy; the greatest abnormalities were seen in the unmyelinated small nerve fibers, a finding that is consistent with the early neuropathic changes seen in the small nerve fibers of patients with impaired glucose tolerance. 14 he biopsies performed at baseline examination also showed that large myelinated fibers, which are the nerve fibers tested in electromyographic studies, were entirely within the reference range for size and number. Relevant to the argument that microvascular disease is present at the early stage of diabetic peripheral neuropathy, the investigators examined the endoneurial vessels and reported the following results: a 4-fold increase in basement membrane thickness, a 2-fold increase in endothelial cell profile number, and a 50% Clinicians surmise that microangiopathy and diabetic peripheral neuropathy are present at an early stage of diabetes mellitus and that microangiopathy progresses with the severity of neuropathy. reduction in the luminal area in the endoneurial vessels in these patients with diabetes and minimal or subclinical neuropathy. Clinicians surmise that microangiopathy and diabetic peripheral neuropathy are present at an early stage of diabetes mellitus and that microangiopathy progresses with the severity of neuropathy. In other words, microvascular disease becomes more prominent as nerves become more damaged, and vice versa. he study described earlier in this article demonstrated that late-stage diabetic peripheral neuropathy is the result of changes occurring over several years, and basement membrane thickness and the endothelial cell profile number correlate with the severity of neuropathy in patients with different stages of neuropathy. 14 hese findings support previous research demonstrating that microvascular disease progressively causes basement membrane thickening, a reduction in luminal area, and alterations in pericytes that lead to nerve damage. 15 he end result of these changes in peripheral nerves and endoneurial blood vessels are shown schematically in Figure 3. Basement membrane thickening, which occurs in the blood vessel and affects the myelinated and unmyelinated nerve fibers, leads to reduced perfusion and hypoxia in the nerve tissue and, ultimately, to nerve death. Figure 3. Microangiopathy and Neuropathy in Peripheral Nerves A schematic representation of a peripheral nerve with basement membrane thickening of the endoneurial vessels and damage to the myelinated and unmyelinated nerve fibers. Advanced Studies in Medicine S147
5 REAMEN OF VASCULAR DYSFUNCION AND NEUROPAHY Because resistance vessels are grossly abnormal in patients with type 2 diabetes mellitus, our research group investigated the commonly used angiotensin II receptor blocker candesartan on the premise that this intervention would restore the blunted vasodilatory response and normalize the shift in blood vessel sensitivity seen in these patients. 16 Patients who had type 2 diabetes mellitus for at least 15 years and normotensive control subjects were randomly assigned to receive candesartan 16 mg or a placebo for 12 weeks; after 12 weeks the patient s sensitivity was normalized and approximately 50% of the vasodilatory response was restored in the patients with diabetes compared to the control subjects. Importantly, the intervention was able to reverse established vascular alterations in the patients with diabetes. A few studies have yielded positive findings in the treatment of neuropathy; only 1 study demonstrates benefits with the angiotensin-converting-enzyme (ACE) inhibitor trandolapril in patients with mild diabetic neuropathy. 17 In that study, treatment with the ACE inhibitor for 12 months resulted in significant and meaningful electromyographic changes, with improvements in nerve conduction velocity, M-wave amplitude, and F-wave latency. However, a review of the molecular basis of diabetic microvascular complications, discussed earlier in this article, suggests several therapeutic targets such as PKC inhibition. Data from early phase II studies of the PKCβ inhibitor ruboxistaurin have been encouraging, as are findings from recently completed and preliminarily reported trials involving patients with diabetic peripheral neuropathy 18,19 and preliminary trial data evaluating the drug in patients with diabetic retinopathy, diabetic macular edema, and diabetic peripheral neuropathy. Ruboxistaurin had a beneficial effect on symptom scores versus a placebo taken over a 12-month period by patients with diabetic peripheral neuropathy (Figure 4). 18 Also, as compared with a placebo taken over the same time period, ruboxistaurin markedly improved scores of 3 measures of nerve function: nerve impairment scores for the lower limbs, reflexes, and lower limbs plus 4 (Figure 5). 19 he positive effects on both symptoms and nerve impairment are particularly encouraging because they are more likely to promote better adherence to therapy over the long term. CONCLUSIONS he key to developing effective treatment for diabetic peripheral neuropathy is to identify the disease s precise cause. Considerable epidemiologic, pathologic, pathophysiologic, and molecular evi- Figure 4. Effects of Ruboxistaurin vs Placebo on Symptom Scores in Diabetic Peripheral Neuropathy Figure 5. Effects of Ruboxistaurin vs Placebo on Nerve Impairment in Diabetic Peripheral Neuropathy Change from baseline Change in Score Improving Placebo 32 mg QD 64 mg QD QD = every day. Data from Vinik et al. 18 P =.072 P =.017 P =.014 P =.357 P =.064 Month 1 Month 3 Month 6 Month 12 P =.049 P =.033 P =.046 NIS (LL) NIS reflex NIS (LL) + 4 Improvement Placebo 32 mg QD n = 205 NIS = nerve impairment score; NIS(LL) = nerve impairment score for the lower limbs; QD = every day. Data from Litchy et al. 19 S148 Vol. 5 (3A) March 2005
6 dence now support the clinical hypothesis that damage to the microvasculature is the underlying cause of diabetic peripheral neuropathy, diabetic nephropathy, and diabetic retinopathy. Molecular studies have shown that mitochondrial oxidative stress drives several key pathways involved in the development of diabetic microvascular complications. herefore, blocking these pathways is a viable approach to therapy. Oxidative stress also drives the functional abnormalities (eg, impaired vasodilation and impaired vascular endothelial sensitivity) that precede structural abnormalities, including basement membrane thickening, in resistance vessels. Basement membrane thickening, a hallmark of diabetic microangiopathy, is present in early stage and latestage diabetic peripheral neuropathy and in patients with impaired glucose tolerance. It is more pronounced in those patients with symptoms of diabetic peripheral neuropathy compared to those patients without symptoms. Pathologic changes in small nerve fibers and epineurial and endoneurial vessels also are present in patients with type 1 and type 2 diabetes mellitus and minimal or subclinical neuropathy. Angiotensin II receptor blockade partially restores the blunted vasodilatory response and normalizes the shift in blood vessel sensitivity in patients with type 2 diabetes mellitus and grossly abnormal resistance vessels. ACE inhibition provides some improvement in nerve function in patients with mild diabetic neuropathy. he most promising therapy for neuropathy may be the inhibition of the PKC pathway with the PKCβ inhibitor ruboxistaurin. Recently completed studies have shown that this agent improves symptom scores and nerve function scores when compared with a placebo. Additional trials evaluating ruboxistaurin in patients with diabetic peripheral neuropathy, diabetic retinopathy, and diabetic macular edema are currently under way. REFERENCES 1. Lundbaek K. he special role of diabetic angiopathy. Horm Metab Res. 1974;(suppl 4): Dyck PJ, Davies JL, Wilson DM, et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999;22: Nishikawa, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404: Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9: Du X, Matsumura, Edelstein D, et al. Inhibition of GADPH activity by poly(adp-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112: esfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39: Coppey LJ, Gellett JS, Davidson EP, et al. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes. 2001;50: Coppey LJ, Gellett JS, Yorek MA. Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effect of diabetes in type 1 and type 2 diabetic rat models. Endothelium. 2003;10: Schofield I, Malik R, Izzard A, et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation. 2002;106: Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24: Novella SP, Inzucchi SE, Goldstein JM. he frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24: Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. he spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60: hrainsdottir S, Malik RA, Dahlin LB, et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes. 2003;52: Malik RA, esfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. In press. 15. Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia. 1989;32: Malik RA, Schofield IJ, Izzard A, et al. he effects of angiotensin type 1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. Hypertension. In press. 17. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998;352: Vinik AI, esfaye S, Zhang D, et al. LY treatment improves diabetic peripheral neuropathy (DPN) with symptoms. Diabetes. 2002;51(suppl 2):A Litchy W, Dyck W, esfaye S, et al. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY treatment. Diabetes. 2002;51(suppl 2):A197. Advanced Studies in Medicine S149
DIABETIC NEUROPATHY ASSESSED AT TWO TIME POINTS FIVE YEARS APART
1 University Department of Neurology, Sarajevo Clinical Center, Sarajevo, Bosnia and Herzegovina 2 Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina 3 Department of Hemodialysis, Sarajevo Clinical
More informationLecture 19 Summary Gestational Diabetes and Complications of Diabetes. Gestational diabetes;
Lecture 19 Summary Gestational Diabetes and Complications of Diabetes Gestational diabetes; - Type of diabetes that only develops during pregnancy Usually diagnosed in late pregnancy Causes high blood
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationCan VEGF reverse diabetic neuropathy in human subjects?
Can VEGF reverse diabetic neuropathy in human subjects? Aristidis Veves, George L. King J Clin Invest. 2001;107(10):1215-1218. https://doi.org/10.1172/jci13038. Commentary Peripheral polyneuropathy is
More informationWatermark. Interaction between Neuropathy and PAD
Interaction between Neuropathy and PAD Javier La Fontaine, DPM, MS Associate Professor Department of Plastic Surgery UT Southwestern Medical Center Dallas, Texas Objectives Understand vascular disease
More informationDiabetic Neuropathy. Nicholas J. Silvestri, M.D.
Diabetic Neuropathy Nicholas J. Silvestri, M.D. Types of Neuropathies Associated with Diabetes Mellitus p Chronic distal sensorimotor polyneuropathy p Focal compression neuropathies p Autonomic neuropathy
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 03 Nov 2018 09:24:50 GMT) CTRI Number Last Modified On 10/06/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPractical upates in Diabetes & CV risk management: Brief Updates Neurological complications in diabetes
Practical upates in Diabetes & CV risk management: Brief Updates Neurological complications in diabetes Slides presented during CDMC in Almaty, Kazakhstan on Sunday April 13, 2014 and prepared by: Boris
More informationEffects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy
Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy J. Guan 1,2, L. Long 1, Y.-Q. Chen 1, Y. Yin 1, L. Li 1, C.-X. Zhang 1, L. Deng 1 and L.-H. Tian
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationVascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy
Diabetologia 2001) 44: 1973±1988 Ó Springer-Verlag 2001 Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy N. E. Cameron 1, S. E.M. Eaton 2, M. A. Cotter 1, S. Tesfaye
More informationKim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism
Kim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism st1 Classification and definition of diabetic neuropathies Painful diabetic peripheral neuropathy Diabetic autonomic neuropathy
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationComplications of Diabetes Mellitus
Complications of diabetes mellitus Complications of Diabetes Mellitus Chronic Complications of Diabetes Mellitus Microvascular Retinopathy (nonproliferative/proliferative) Nephropathy Neuropathy Sensory
More informationORIGINAL CONTRIBUTION. Value of the Oral Glucose Tolerance Test in the Evaluation of Chronic Idiopathic Axonal Polyneuropathy
ORIGINAL CONTRIBUTION Value of the Oral Glucose Tolerance Test in the Evaluation of Chronic Idiopathic Axonal Polyneuropathy Charlene Hoffman-Snyder, MSN, NP-BC; Benn E. Smith, MD; Mark A. Ross, MD; Jose
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationSlide notes: The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important
1 2 The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important role. They comprise microangiopathy, diabetic retinopathy, diabetic
More informationEpidemiology and Pathophysiology of Diabetic Retinopathy
Epidemiology and Pathophysiology of Diabetic Retinopathy Vincent Reppucci, MD Director, Retina Service Mt. Sinai St. Luke s-roosevelt Hospital Attending Physician, Retina Service New York Eye and Ear Infirmary
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationChapter 14 Blood Vessels, Blood Flow and Pressure Exam Study Questions
Chapter 14 Blood Vessels, Blood Flow and Pressure Exam Study Questions 14.1 Physical Law Governing Blood Flow and Blood Pressure 1. How do you calculate flow rate? 2. What is the driving force of blood
More informationDiabetic Neuropathy: Discordance between Symptoms and Electrophysiological Testing in Saudi Diabetics
Bahrain Medical Bulletin, Vol.24, No.1, March 2002 Diabetic Neuropathy: Discordance between Symptoms and Electrophysiological Testing in Saudi Diabetics Daad H Akbar, FRCP(UK), Arab Board, Saudi Board
More informationDiabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines
Diabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines Richard Arakaki, M.D. Phoenix Area Diabetes Consultant August 9 th 2018 Disclose no conflict of interest Complications and Co-morbidities
More informationInsulin Neuritis: an old, but still an unfamiliar and mysterious condition
Insulin Neuritis: an old, but still an unfamiliar and mysterious condition Authors: Yun Tae Hwang 1, Gerard Davies 1 1. Department of Neurology, Royal Free Hospital, United Kingdom Corresponding author:
More informationDiabetes is associated with increased risk
DIABETIC PERIPHERAL NEUROPATHY: ADVANCES IN UNDERSTANDING AND TREATMENT * Vera Bril, MD, PhD, FRCP ABSTRACT Diabetic peripheral neuropathy (DPN) affects approximately 50% of patients with diabetes and
More informationEvaluation of nerve conduction abnormalities in type 2 diabetic patients
Original article: Evaluation of nerve conduction abnormalities in type 2 diabetic patients 1Kannan K, 2 Sivaraj M 1Asst Professor, Dept of Physiology, kilpauk Medical College, Kilpauk, Chennai, Tamil Nadu,
More informationPeripheral neuropathy is common in diabetes,
Endoneurial Capillary Abnormalities Presage Deterioration of Glucose Tolerance and Accompany Peripheral Neuropathy in Man Soley Thrainsdottir, 1 Rayez A. Malik, 2 Lars B. Dahlin, 3 Peter Wiksell, 4 Karl
More informationNo Difference in Small or Large Nerve Fiber Function Between Individuals With Normal Glucose Tolerance and Impaired Glucose Tolerance
No Difference in Small or Large Nerve Fiber Function Between Individuals With Normal Glucose Tolerance and Impaired Glucose Tolerance Pourhamidi, Kaveh; Dahlin, Lars; Englund, Elisabet; Rolandsson, Olov
More informationPainful Diabetic Neuropathy Is Associated With Greater Autonomic Dysfunction Than Painless Diabetic Neuropathy
Pathophysiology/Complications O R I G I N A L A R T I C L E Painful Diabetic Neuropathy Is Associated With Greater Autonomic Dysfunction Than Painless Diabetic Neuropathy RAJIV A. GANDHI, MRCP 1 JEFFERSON
More informationPROCEEDINGS NEW TRENDS IN THE MANAGEMENT OF DIABETIC RETINOPATHY* Paul M. Dodson, MD, FRCP, FRCOphth ABSTRACT
NEW TRENDS IN THE MANAGEMENT OF DIABETIC RETINOPATHY Paul M. Dodson, MD, FRCP, FRCOphth ABSTRACT Based on a presentation given by Dr Dodson at a symposium held in conjunction with the 12th International
More informationComparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
Comparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP Samantha K. Dunnigan 1, Hamid Ebadi 1, Ari Breiner 1, Hans D. Katzberg 1, Leif E. Lovblom
More informationManaging Diabetic Peripheral Neuropathic Pain
Managing Diabetic Peripheral Neuropathic Pain Juzar Hooker Consulting Neurologist, Aga Khan University Hospital, Nairobi juzar.hooker@aku.edu Disclosure Eli lilly (have not driven, reviewed or controlled
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationClinical and Electrodiagnostic Profile of Diabetic Neuropathy in a Tertiary Hospital in Punjab, India
ORIGINAL ARTICLE Clinical and Electrodiagnostic Profile of Diabetic Neuropathy in a Tertiary Hospital in Punjab, India Vishali Kotwal, Amit Thakur* Abstract Peripheral neuropathy is commonly seen in diabetic
More informationPlease print clearly; illegible forms will delay your receiving credit/verification: City State ZIP. Yes No
PARTICIPANT INFORMATION Please print clearly; illegible forms will delay your receiving credit/verification: First Name MI Last Name Address 1 Address 2 City State ZIP Country Daytime Telephone Fax E-mail
More information25 Protein Kinase C Inhibitors and
25 Protein Kinase C Inhibitors and Diabetic Microvascular Disease Arvind Gupta, Rajeev Gupta Abstract: Diabetes is characterized by major changes in the microvascular system. Multiple pathways exist that
More informationDIAGNOSIS OF DIABETIC NEUROPATHY
DIAGNOSIS OF DIABETIC NEUROPATHY Dept of PM&R, College of Medicine, Korea University Dong Hwee Kim Electrodiagnosis ANS Clinical Measures QST DIAGRAM OF CASUAL PATHWAYS TO FOOT ULCERATION Rathur & Boulton.
More informationThe World Health Organization (WHO) has described diabetes mellitus as Metabolic
1.1. Background The World Health Organization (WHO) has described diabetes mellitus as Metabolic disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrate,
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationCritical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM. Andrzej Sladkowski
Critical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM Andrzej Sladkowski Potential causes of weakness in the ICU-1 Muscle disease Critical illness myopathy Inflammatory myopathy Hypokalemic
More information(D) (E) (F) 6. The extrasystolic beat would produce (A) increased pulse pressure because contractility. is increased. increased
Review Test 1. A 53-year-old woman is found, by arteriography, to have 5% narrowing of her left renal artery. What is the expected change in blood flow through the stenotic artery? Decrease to 1 2 Decrease
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationNeurophysiological evaluation in newly diagnosed Diabetes Mellitus type 1
Cent. Eur. J. Med. 8(4) 2013 503-508 DOI: 10.2478/s11536-013-0181-6 Central European Journal of Medicine Neurophysiological evaluation in newly diagnosed Diabetes Mellitus type 1 Dragana Matanovic* 1,2,
More informationMædica - a Journal of Clinical Medicine. University of Oradea, Institute for Doctoral Studies, Oradea, Bihor County, Romania
MAEDICA a Journal of Clinical Medicine 2018; 13(3): 229-234 https://doi.org/10.26574/maedica.2018.13.3.229 Mædica - a Journal of Clinical Medicine Original paper Diabetic Neuropathy Prevalence and Its
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationORIGINAL ARTICLE. STUDY OF CLINICO ELECTROPHYSIOLOGICAL PROFILE OF DIABETIC NEUROPATHY Sachin. G. J, Ravi Vaswani, Shilpa. B.
STUDY OF CLINICO ELECTROPHYSIOLOGICAL PROFILE OF DIABETIC NEUROPATHY Sachin. G. J, Ravi Vaswani, Shilpa. B. 1. Assistant Professor, Department of Medicine, Vijayanagara Institute of Medical Sciences. Bellary.
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationTYPE 2 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE FILE
06 May, 2018 TYPE 2 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE FILE Document Filetype: PDF 237.65 KB 0 TYPE 2 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE FILE Recommendations for
More informationElectrophysiological Changes in Patients with Impaired Glucose Tolerance
Turkish Journal of Endocrinology and Metabolism, (2000) 4 : 123-128 Electrophysiological Changes in Patients with Impaired Glucose Tolerance Serdar Güler* Dilek Berker** Hüseyin Tu rul Atasoy*** Bekir
More informationTreatment Induced Neuropathy of Diabetes. Christopher Gibbons MD, MMSc
Treatment Induced Neuropathy of Diabetes Christopher Gibbons MD, MMSc Background 1. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Annals of neurology
More informationDiabetic foot ulcers: improved microcirculation after low-energy laser irradiation
Diabetic foot ulcers: improved microcirculation after low-energy laser irradiation V. Urbančič-Rovan 1, 2, A. Bernjak 3, 4, B. Sedej 5 and A. Stefanovska 3,4 1 University Medical Centre, Dept of Endocrinology,
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationRecognizing the earliest alteration of
Pathophysiology/Complications O R I G I N A L A R T I C L E Monotonicity of Nerve Tests in Diabetes Subclinical nerve dysfunction precedes diagnosis of polyneuropathy PETER J. DYCK, MD 1 PETER C. O BRIEN,
More informationThe metabolic memory. Antonio Ceriello
The metabolic memory Antonio Ceriello : DCCT/EDIC - Long-term Microvascular Risk Reduction in Type 1 Diabetes A1C 12% 10% Intensive Retinopathy progression (incidence) Conventional 0.5 0.4 0.3 62% risk
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationObese Type 2 Diabetic Model. Rat Model with Early Onset of Diabetic Complications. SDT fatty rats. SDT fatty rats
Obese Type 2 Diabetic Model rats Rat Model with Early Onset of Diabetic Complications rats Background and Origin In 24, Dr. Masuyama and Dr. Shinohara (Research Laboratories of Torii Pharmaceutical Co.,
More informationThe Efficacy Of Hyperbaric Oxygen Theraphy For The Treatment Of Diabetic Autonomic Neuropathy
ISPUB.COM The Internet Journal of Neurology Volume 1 Number 2 The Efficacy Of Hyperbaric Oxygen Theraphy For The Treatment Of Diabetic Autonomic Neuropathy M Isguzar, C Top, O Öncül, S Çavuslu, E Elbüken,
More informationClinician-reported Sign Outcome Measures of CIPN
Clinician-reported Sign Outcome Measures of CIPN A. Gordon Smith, MD FAAN Professor and Vice Chair of Neurology Chief, Division of Neuromuscular Medicine University of Utah School of Medicine Examination/Sign
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationPhysiology Unit 3 CARDIOVASCULAR PHYSIOLOGY: THE VASCULAR SYSTEM
Physiology Unit 3 CARDIOVASCULAR PHYSIOLOGY: THE VASCULAR SYSTEM In Physiology Today Hemodynamics F = ΔP/R Blood flow (F) High to low pressure Rate = L/min Pressure (P) Hydrostatic pressure Pressure exerted
More informationIntroduction 1 CHAPTER I INTRODUCTION
Introduction 1 CHAPTER I INTRODUCTION World Health Organisation (W.H.O.) projected an increase of diabetes which has already reached epidemic proportions, particularly in urban India. Possibly by the year
More informationSpecial circulations, Coronary, Pulmonary. Faisal I. Mohammed, MD,PhD
Special circulations, Coronary, Pulmonary Faisal I. Mohammed, MD,PhD 1 Objectives Describe the control of blood flow to different circulations (Skeletal muscles, pulmonary and coronary) Point out special
More informationHBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT
Basrah Journal Of Surgery Bas J Surg, September, 18, 2012 HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT MB,ChB, DA, FICMS, Lecturer in Anesthesiology, Department of Surgery, College of Medicine,
More informationGlomerular Filtration Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.
Glomerular Filtration Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Introduction Formation of urine by the kidney involves
More informationBIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1
BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1 Terms you should understand: hemorrhage, intrinsic and extrinsic mechanisms, anoxia, myocardial contractility, residual
More informationCASE 13. What neural and humoral pathways regulate arterial pressure? What are two effects of angiotensin II?
CASE 13 A 57-year-old man with long-standing diabetes mellitus and newly diagnosed hypertension presents to his primary care physician for follow-up. The patient has been trying to alter his dietary habits
More informationINTRODUCTION AND SYMPTOMS
CHAPTER 1 INTRODUCTION AND SYMPTOMS Introduction of Diabetic Retinopathy Diabetic retinopathy (DR) is a potentially blinding complication of diabetes. It is defined as presence of one or more definite
More informationA pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy
A pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy El-Orabi HA 1, Halawa MR 1, Abd El-Salam MM 1, Eliewa TF 2 and Sherif NSE 1 Internal Medicine and Endocrinology
More informationAlpha-Lipoic Acid: A Versatile Antioxidant VRM
Alpha-Lipoic Acid: A Versatile Antioxidant VRM By Yousry Naguib, PhD Alpha-lipoic acid (also known as thioctic acid) is produced in the body, and found in food sources such as liver, brewer's yeast, and
More informationCHRONIC COMPLICATIONS OF DIABETES MELLITUS
CHRONIC COMPLICATIONS OF Microvascular complications: Diabetic retinopathy Diabetic nephropathy Diabetic neuropathy Macrovascular complications DIABETES MELLITUS Systemic atheroscerosis Mixted: diabetic
More informationEFFECT OF GLYCEMIC CONTROL ON ELECTROPHYSIOLOGIC CHANGES OF DIABETIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS
EFFECT OF GLYCEMIC COTROL O ELECTROPHYSIOLOGIC CHAGES OF DIABETIC EUROPATHY I TYPE 2 DIABETIC PATIETS Chun-Chiang Huang, Tien-Wen Chen, 1 Ming-Cheng Weng, 1 Chia-Ling Lee, Hsiang-Chieh Tseng, 2 and Mao-Hsiung
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationPROCEEDINGS THE IMPORTANCE OF ENDOTHELIAL DAMAGE: DIABETIC RETINOPATHY* Massimo Porta, MD, PhD ABSTRACT
THE IMPORTANCE OF ENDOTHELIAL DAMAGE: DIABETIC RETINOPATHY* Massimo Porta, MD, PhD ABSTRACT Diabetic retinopathy is the leading cause of blindness in adults of working age in industrialized countries and
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationWhat is the mechanism of the audible carotid bruit? How does one calculate the velocity of blood flow?
CASE 8 A 65-year-old man with a history of hypertension and coronary artery disease presents to the emergency center with complaints of left-sided facial numbness and weakness. His blood pressure is normal,
More informationThe Autonomic Nervous System Outline of class lecture for Physiology
The Autonomic Nervous System Outline of class lecture for Physiology 1 After studying the endocrine system you should be able to: 1. Describe the organization of the nervous system. 2. Compare and contrast
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationPathology of endocrine pancreas. By: Shifaa Alqa qa
Pathology of endocrine pancreas By: Shifaa Alqa qa major cell types: Beta ----- insulin Alpha ----- glucagon Delta ----- somatostatin PP (pancreatic polypeptide) cells ------ VIP DIABETES MELLITUS Normal
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationHeart. Large lymphatic vessels Lymph node. Lymphatic. system Arteriovenous anastomosis. (exchange vessels)
Venous system Large veins (capacitance vessels) Small veins (capacitance vessels) Postcapillary venule Thoroughfare channel Heart Large lymphatic vessels Lymph node Lymphatic system Arteriovenous anastomosis
More informationDiabetic retinopathy (DR) represents a
THE MOLECULAR BIOLOGY OF DIABETIC RETINOPATHY: OPPORTUNITIES FOR THERAPEUTIC INTERVENTION Lloyd P. Aiello, MD, PhD ABSTRACT Hyperglycemia is the principal underlying cause of diabetic microvascular complications,
More informationAntioxidant Status in Type 2 Diabetic Neuropathy. Isam Hamo Mahmood, Ph.D* Kassim Salih Abdullah Al Neaimy, Ph.D*
Bahrain Medical Bulletin, Volume 30, No 1, March 2008 Antioxidant Status in Type 2 Diabetic Neuropathy Isam Hamo Mahmood, Ph.D* Kassim Salih Abdullah Al Neaimy, Ph.D* Objective: To measure the concentration
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationCardiovascular System. Blood Vessel anatomy Physiology & regulation
Cardiovascular System Blood Vessel anatomy Physiology & regulation Path of blood flow Aorta Arteries Arterioles Capillaries Venules Veins Vena cava Vessel anatomy: 3 layers Tunica externa (adventitia):
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationMicroangiopathy in diabetic polyneuropathy revisited
European Review for Medical and Pharmacological Sciences 2018; 22: 6456-6462 Microangiopathy in diabetic polyneuropathy revisited F. FANG 1, J. WANG 2, Y.-F. WANG 1, Y.-D. PENG 1 1 Shanghai General Hospital,
More informationVascular Structural and Functional Changes in Type 2 Diabetes Mellitus. Evidence for the Roles of Abnormal Myogenic Responsiveness and Dyslipidemia
Vascular Structural and Functional Changes in Type 2 Diabetes Mellitus Evidence for the Roles of Abnormal Myogenic Responsiveness and Dyslipidemia Ian Schofield, MRCP; Rayaz Malik, PhD, MRCP; Ashley Izzard,
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationThe Circulatory System
The Circulatory System Dr. Sami Zaqout The circulatory system Circulatory system Blood vascular systems Lymphatic vascular systems Blood vascular systems Blood vascular systems The circulatory system Circulatory
More informationBenfotiamine. Benfotiamine. Monograph
H 3 C N N NH 2 CH 2 N CH 3 O C C CH 2 CH 2 O P OH CHO S OC OH Introduction Neurological disorders, particularly diabetic neuropathy, have been treated with vitamin B1 (thiamine) for decades; however, the
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationVascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy. Mark A.
Reprint from The Review of DIABETIC STUDIES Vol 12 No 12 2015 Special Edition Microvascular Complications of Diabetes The Review of DIABETIC STUDIES REVIEW Vascular Impairment of Epineurial Arterioles
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationThe Beneficial Effect of Asiaticoside on Experimental Neuropathy in Diabetic Rats
American Journal of Applied Sciences, 2012, 9 (11), 1782-1788 ISSN 1546-9239 2012 Science Publication doi:10.3844/ajassp.2012.1782.1788 Published Online 9 (11) 2012 (http://www.thescipub.com/ajas.toc)
More informationBiomechanics of Pain: Dynamics of the Neuromatrix
Biomechanics of Pain: Dynamics of the Neuromatrix Partap S. Khalsa, D.C., Ph.D. Department of Biomedical Engineering The Neuromatrix From: Melzack R (1999) Pain Suppl 6:S121-6. NIOSH STAR Symposium May
More informationChapter 24 Diabetes Mellitus
Chapter 24 Diabetes Mellitus Classification of Diabetes Mellitus Acute Effects of Diabetes Mellitus Chronic Complications of Diabetes Mellitus: Early Stages Chronic Complications of Diabetes Mellitus:
More informationHigh Risk Podiatry in a Vascular Setting; A new paradigm in Diabetic Foot Disease? Ereena Torpey Senior Podiatrist - FMC
High Risk Podiatry in a Vascular Setting; A new paradigm in Diabetic Foot Disease? Ereena Torpey Senior Podiatrist - FMC A new paradigm? Foot ulceration 101 Assessing Perfusion a new challenge Pressure
More informationDiabetes Mellitus. Disorder of metabolism (Carb, Prot & Fat) Due to Absolute/relative deficiency of insulin. Characterized by hyperglycemia.
Diabetes Mellitus Disorder of metabolism (Carb, Prot & Fat) Due to Absolute/relative deficiency of insulin. Characterized by hyperglycemia. Clinically : Polyuria, Polydypsia, Polyphagia. Diabetes Classification
More information